beamtx.com - BEAM Company profit before taxes, interest and amortization
Beam Therapeutics Inc. (BEAM) relies on a secure liquidity buffer and the success of base editing genome technology. Tracking the chart on GURU.Markets, we note that EBITDA reached 0.00, reflecting the current level of this metric. The foundation consists of robotic therapy synthesis stations and the implementation of AI to accelerate molecular drug screening.
Beam Therapeutics (BEAM) - metric breakdowns and financial figures
- stock quotes and analyst forecast:
- issuer market value details:
- issuer book value statistics:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Beam Therapeutics Inc.|BEAM - Long-Term Debt to Capital|Short-Term Debt to Capital Beam Therapeutics Inc|BEAM - Company Debts|Debts to Book Capitalization Ratio Beam Therapeutics|BEAM - Company Long-Term Debts|Short-Term Debt Beam Therapeutics|Quick Ratio beamtx.com
- earnings and market ratios statistics:
BEAM - Net Income|Future Net Profit Beam Therapeutics Inc.|BEAM - P/E Multiple|Market Cap to Projected Earnings beamtx.com|BEAM - PEG Multiple|Enterprise Value to EBITDA Ratio Beam Therapeutics|BEAM - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Beam Therapeutics|BEAM - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months beamtx.com|BEAM - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Beam Therapeutics Inc.
- sales revenue and business income indicators:
Analysis of all company metrics:Beam Tx, BEAM
For the non-cyclical gene editing business of Beam Therapeutics Inc. (BEAM), the key factor is the ability to generate cash flow to cover expensive R&D costs. This indicator captures net operating income before depreciation, interest, and taxes, reflecting the real efficiency of capital management. By analyzing the EBITDA trend, an investor can assess the company's resilience to borrowing costs and the risks of potential drawdowns.
Who Beam Therapeutics Inc. competes with
Income before deduction of interest, taxes and amortization TEM|QGEN: Operating profit before deduction of amortization|ionispharma.com - Company profit before taxes, interest and amortization|RGEN: Operating profit EBITDA|Avidity Biosciences Inc - Income before deduction of interest, taxes and amortization|CRSP (CRISPR Therapeutics Corp) - Operating profit EBITDA|Profit before interest, taxes and amortization GeneDx Corp WGS|Profit before payment of interest, taxes and amortization Ultragenyx Pharmaceutical (RARE)|SRPT (sarepta.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA TWST (Twist Bioscience, Inc.)|Operating profit EBITDA 10x Genomics Inc TXG|NTLA - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization STOK|BLFS: Operating profit EBITDA|Profit before interest, taxes and amortization wavelifesciences.com (WVE)|Operating profit before deduction of amortization MAZE|Operating profit EBITDA Sionna Therapeutics, Inc.|Operating profit before deduction of amortization PRME (Prime Medicine Corp)|Company profit before taxes, interest and amortization TSHA|Operating profit EBITDA QURE (uniQure N.V.)|Operating income before deduction of amortization meiragtx.com (MGTX)|REGENXBIO - Operating profit EBITDA|Solid Biosciences Inc (SLDB) - Operating profit before deduction of amortization|Ocugen Corp (OCGN) - Profit before payment of interest, taxes and amortization|PACB - Operating income before deduction of amortization|Operating profit before deduction of amortization BNTC|DSGN: Income before deduction of interest, taxes and amortization|Operating profit EBITDA RCKT|Operating income before deduction of amortization 4DMT|Profit before payment of interest, taxes and amortization Lexeo Therapeutics, Inc. LXEO|KRRO: Operating profit before amortization|Editas Medicine, Inc. - Operating profit EBITDA|silence-therapeutics.com (SLN) - Operating profit before deduction of amortization|PRQR (proqr.com) - Operating profit before deduction of amortization|CDXS - Operating income before deduction of amortization|SGMO (Sangamo) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization NAUT|Operating profit EBITDA MGX|DTIL - Profit before interest, taxes and amortization|Operating profit EBITDA GBIO (Generation Bio)|Operating profit EBITDA Boundless Bio Inc. BOLD|XCUR - Profit before payment of interest, taxes and amortization|Imunon, Inc. (IMNN) - Operating profit before deduction of amortization|PHIO: Operating profit EBITDA|Operating profit before amortization MBIO|Profit before payment of interest, taxes and amortization TransCode Therapeutics Inc.|Operating profit before amortization BNGO (Bionano)|Operating profit EBITDA APDN|Operating profit EBITDA bluebird bio, Inc (BLUE)|Operating profit EBITDA IPA (ImmunoPrecise Antibodies Ltd.)|omegatherapeutics.com - Profit before payment of interest, taxes and amortization|Singular Genomics - Operating profit EBITDA|Profit before interest, taxes and amortization Regulus Therapeutics, Inc.|SYRS: Operating profit EBITDA|Telesis Bio, Inc (TBIO) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization TRACON Pharmaceuticals|Operating profit before deduction of amortization unitybiotechnology.com (UBX)
